Lean and mean, outsourcing oncology machine: Anixa Biosciences, Inc.

He’s got patents, patience, and a plan – and a five-year runway to execute. Listen in as Dr. Amit Kumar, CEO of Anixa Biosciences, tells a tale of novel vaccines for breast, and ovarian cancer, and a new kind of CAR-T therapy – also for ovarian cancer – called a CER-T: a Chimeric Endocrine Receptor T cell. Is it worth your investment? Cleveland Clinic, Moffit Cancer Center, and investigators at NIH seem to think so…